钠–葡萄糖协同转运蛋白2（SGLT2）抑制剂是近年来降糖药研究的新热点，通过抑制肾小管上皮细胞内的主要血糖转运蛋白SGLT2降低肾内滤过葡萄糖的重吸收，导致糖尿，从而降低血清内葡萄糖。新型SGLT2抑制剂empagliflozin具有良好的降糖效果，单次给药就能显著增加尿中排糖，多次给药后剂量相关性地降低FPG、HbA1c和体质量，作为补充药物治疗还能显著降低血压，目前正在进行Ⅲ期临床试验。

Sodium-glucose linked transporter 2 (SGLT2) inhibitor is a hot target for hypoglycemic agents in recent years, by inhibiting the main glucose transporter SGLT2 in renal tubular epithelial cells to reduce renal glucose reabsorption filtration, resulting in urine glucose excretion and reducing serum glucose concentration. New SGLT2 inhibitor empagliflozin has good hypoglycemic effects, single dosing can significantly increase urine glucose excretion, after multiple dosing, FPG, HbA1c, and body weight were decreased in a dose-dependent manner. As a supplementary drug, empagliflozin significantly reduces blood pressure and now is undergoing phase III clinical trials.